Bharat Biotech Introduces India's First Integrated Cell & Gene Therapy

Bharat Biotech International Limited (BBIL) has expanded its expertise from vaccine innovation to cutting-edge regenerative and personalized therapies that offer hope to millions of people by establishing India's only vertically integrated, purpose-designed cell & gene therapy (CGT) infrastructure & viral vector production facility at Genome Valley.

The work will range from strengthening immune responses against cancer to making sure that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia. This facility ushers in a new era of gene and cell therapies to address scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival.

In BBIL's long-standing mission to provide targeted, life-saving treatments that address unmet clinical needs globally by focusing on critical conditions like haematological malignancies and inherited blood disorders, the 50,000-square-foot dedicated state-of-the-art CGT facility marks the next milestone.

Dr Krishna Ella, executive chairman, Bharat Biotech said, “Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialized manufacturing capabilities. With our extensive experience and proven excellence in viral vaccine manufacturing is uniquely positioned to master these complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases.”